You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in the United Kingdom

Jun 2012

Price: US$2,400

About this Report

EXECUTIVE SUMMARY

Growth despite tough trading conditions and policy uncertainty

Despite difficult economic conditions in the UK, and the increasing traction gained by private label and generic alternatives, consumer health saw overall value growth in 2011, thanks in particular to the strong performance of categories related to lifestyle moderation and improvement, and those which have seen greater degrees of brand innovation.

Sports nutrition hits the mainstream while other categories return to the margins

Sports nutrition continued to be the star performer in consumer health in 2011, with double digit growth experienced, which is expected to continue in the forecast period. The leading player in the category was acquired by GlaxoSmithKline late in 2010, and saw significant marketing spend in 2011. This is a clear sign that the industry is well on the way to becoming mainstream and extending its consumer base among the significant portion of the UK population who exercise regularly but who have not previously considered purchasing sports nutrition products. In contrast, the OTC obesity category, which was created by from EU-wide switch of Alli in 2009, and initially saw huge growth, has moved firmly back to the margins, as Alli has failed to continue its initial strong performance.

Innovation the key for brands to compete with private label

In 2011, private label continued to increase its share in several categories, particularly those in which consumers have increasingly become more ingredient conscious. More worryingly for brands, there has also been an extension of the reach of private labels into product areas in which its penetration has traditionally been limited by consumer confidence. In response, brands have undertaken significant outlay both on innovation and marketing campaigns, with combination, value-added and “lifestyle improving” products being seen as vital to the successful combating of private label encroachment.

Supermarkets and internet retailing gain share but specialists fight back

Supermarkets have been steadily gaining share across categories such as analgesics, cough and cold remedies and medicated confectionery, as a result of consumers’ increasing confidence in private label and generic alternatives. Price differentials can be significant, and brands have ceded market share to private label. Indeed in 2011, private label extended its reach into previously under-inhabited categories, such as weight management and NRT smoking cessation aids. While internet retailing is still a relatively small distribution channel in consumer healthcare, it is rapidly gaining share, in particular in vitamins and dietary supplements.

Growth picks up marginally over the forecast period

The review period CAGR was -1.8%, the forecast period CAGR is 1.0%, therefore growth is predicted to faster, not slower.] This is due to ongoing sluggishness in the UK economy with projected growth rates having continually been revised downwards over the course of 2011 and early 2012. It is also a function of the increasing prevalence of private label and generic products in the market. Such products will maintain volume levels but tend to hamper value growth. The main branded players in the market must concentrate on sustaining a pipeline of value-added products and developing offerings which reflect the shifting demographics of the UK population, and trends such as the desire for preventative self-medication and more robust general health.


Samples (FAQs about samples):

doc_pdf.png Sample Consumer Health Market Research Report

doc_excel_table.png Sample Consumer Health Data

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in United Kingdom with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in United Kingdom, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in United Kingdom for free:

The Consumer Health in United Kingdom market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in United Kingdom?
  • What are the major brands in United Kingdom?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Table of Contents

Table of Contents

Consumer Health in the United Kingdom - Industry Overview

EXECUTIVE SUMMARY

Growth despite tough trading conditions and policy uncertainty

Sports nutrition hits the mainstream while other categories return to the margins

Innovation the key for brands to compete with private label

Supermarkets and internet retailing gain share but specialists fight back

Growth picks up marginally over the forecast period

KEY TRENDS AND DEVELOPMENTS

Opportunities for growth in a dire economic climate

Current impact

Outlook

Future impact

Innovation key for differentiation and market capture

The days of stellar switches are over (for now)

Uncertain outlook for traditional herbal products

Promoting responsible self-medication: Where profit meets policy

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2006-2011
  • Table 2 Life Expectancy at Birth 2006-2011

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2006-2011
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2006-2011
  • Table 5 Consumer Health Company Shares 2007-2011
  • Table 6 Consumer Health Brand Shares 2008-2011
  • Table 7 Penetration of Private Label by Category 2006-2011
  • Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
  • Table 9 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
  • Table 10 Forecast Sales of Consumer Health by Category: Value 2011-2016
  • Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016

APPENDIX

OTC registration and classification

EU legislation

UK environment

Self-medication/self-care and preventative medicine

Switches

  • Summary 1 OTC Switches 2009-2011

SOURCES

  • Summary 2 Research Sources

Consumer Health in the United Kingdom - Company Profiles

Boots UK Ltd in Consumer Health (United Kingdom)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 5 BCM: Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 6 Boots UK Ltd: Competitive Position 2011

Forest Laboratories UK Ltd in Consumer Health (United Kingdom)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 8 Forest Laboratories UK Ltd: Competitive Position 2011

GlaxoSmithKline Plc in Consumer Health (United Kingdom)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 10 GlaxoSmithKline Plc: Competitive Position 2011

GR Lane Health Products Ltd in Consumer Health (United Kingdom)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 12 GR Lane Health Products: Competitive Position 2011

Healthspan Group Ltd in Consumer Health (United Kingdom)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 14 Healthspan Group Ltd: Competitive Position 2011

Holland & Barrett Retail Ltd in Consumer Health (United Kingdom)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 17 Holland & Barrett Retail Ltd: Competitive Position 2011

Maxinutrition Ltd in Consumer Health (United Kingdom)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 19 Maxinutrition Ltd: Competitive Position 2011

McNeil Healthcare (UK) Ltd in Consumer Health (United Kingdom)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 21 McNeil Healthcare UK Ltd: Competitive Position 2011

Reckitt Benckiser Plc in Consumer Health (United Kingdom)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 24 Reckitt Benckiser Plc: Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 25 Reckitt Benckiser Plc: Competitive Position 2011

Vitabiotics Ltd in Consumer Health (United Kingdom)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 28 Vitabiotics Ltd: Competitive Position 2011

Adult Mouth Care in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • In 2011, adult mouth care achieved sales worth £35 million, an increase of 5% in current value terms from 2010. The category will remain fairly static over the forecast period, with marginal growth achieved by new products and innovations in a concentrated and flat market. The UK’s expanding ageing population offers long-term growth prospects for adult mouth care as the elderly are more likely to suffer from mouth disease, for example dry mouth, increasing the demand for treatment.

SWITCHES

COMPETITIVE LANDSCAPE

  • Reckitt Benckiser Plc is the leader in adult mouth care in the UK, with a 29% value share in 2011. It has maintained its strong position through innovation. The company’s brand Bonjela Complete Plus, for example, is a small easily applicable product that forms a protective barrier over mouth ulcers that quickens the healing process.

PROSPECTS

  • The adult mouth care market value is expected to increase marginally over the forecast period, in constant value terms. Long-term growth prospects are more positive, as a growing elderly population will increase demand for adult mouth care products, particularly for products that treat dry mouth

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2006-2011
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2006-2011
  • Table 14 Adult Mouth Care Company Shares by Value 2007-2011
  • Table 15 Adult Mouth Care Brand Shares by Value 2008-2011
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2011-2016
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2011-2016

Analgesics in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • Retail value sales of analgesics in the UK declined marginally in 2011, to £518 million. The overall category continues to suffer in value terms from the growth of private label. Consumers are becoming increasingly canny about the type of products which are available and are increasingly willing to purchase on ingredient rather than brand name.

SWITCHES

COMPETITIVE LANDSCAPE

  • Reckitt Benckiser Plc, GlaxoSmithKline Plc and McNeil Healthcare (UK) Ltd together accounted for some 52% of retail sales in the overall analgesics category in 2011.

PROSPECTS

  • Over the forecast period, analgesics are expected to show positive value growth, with a constant value CAGR of 2%, to reach £564 million at constant 2011 prices by 2016. While the increasing importance and acceptance of private label within the category will continue to lead to price pressure and promotions, brand manufacturers are displaying the ability to innovate and add value, which will be required to maintain value in the category.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2006-2011
  • Table 19 Sales of Analgesics by Category: % Value Growth 2006-2011
  • Table 20 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2006-2011
  • Table 21 Analgesics Company Shares by Value 2007-2011
  • Table 22 Analgesics Brand Shares by Value 2008-2011
  • Table 23 Forecast Sales of Analgesics by Category: Value 2011-2016
  • Table 24 Forecast Sales of Analgesics by Category: % Value Growth 2011-2016

Calming and Sleeping in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • In 2011, sales of calming and sleeping products increased by 5%, to reach a value of £47 million. This category is dominated by a few leading market players and private label. The use of herbal and natural remedies to aid sleep is increasing, and has led to most branded manufacturers adding herbal variants to their product listings.

SWITCHES

COMPETITIVE LANDSCAPE

  • In 2011, GR Lane Health Products Ltd led the calming and sleeping products environment, holding a value share of 35%. The company further extended its Kalms Sleep range by introducing a new herbal variant: Kalms Night One-a-Night. The new product contains dry extract of the plant valerian, which is said to have natural sedative qualities. GR Lane backed the launch of Kalms Night One-a-Night with a TV advertising and PR campaign, and has produced a consumer advice leaflet for its Kalms range, with information on coping with insomnia and sleeplessness.

PROSPECTS

  • Sales of calming and sleeping products are predicted to grow by a 1% CAGR in constant value terms over the forecast period, as economic conditions continue to be poor and stress levels increase, driving demand for calming and sleeping remedies.

CATEGORY DATA

  • Table 25 Sales of Calming and Sleeping: Value 2006-2011
  • Table 26 Sales of Calming and Sleeping: % Value Growth 2006-2011
  • Table 27 Calming and Sleeping Company Shares by Value 2007-2011
  • Table 28 Calming and Sleeping Brand Shares by Value 2008-2011
  • Table 29 Forecast Sales of Calming and Sleeping: Value 2011-2016
  • Table 30 Forecast Sales of Calming and Sleeping: % Value Growth 2011-2016

Cough, Cold and Allergy (Hay Fever) Remedies in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • In 2011, the cough, cold and allergy remedies category grew by 2%, to reach £622 million. Although nasal decongestion plasters is the fastest growing category, it is growing from a very small base. Combination remedies that treat all cold and flu symptoms, and longer lasting extra strength products are driving the market. Consumers with tighter budgets are turning to these products as a “one-stop shop”

SWITCHES

COMPETITIVE LANDSCAPE

  • In 2011, GlaxoSmithKline Plc (GSK) was the category leader, with a 20% value share. The company’s continuous investment and innovation has led to its leading status. GSK leads the fast growing combination products category, with a 42% value share. It was the first company to bring the “all-in-one” concept to the market, with its Beechams portfolio, and has boosted this range in recent years with the launch of Beechams All-in-One Ultra, adding an extra strength product to a successful portfolio. The company continues to develop new combination products, and in January 2011, it replaced its Contac 12 hour relief decongestion medicine with Contac Dual Relief. This pharmacy-only product comprises tablets containing 30mg pseudoephedrine hydrochloride and 500mg paracetamol. The packaging highlights that the medicine clears nasal and sinus congestion, and relieves headache and pain. In an initiative to boost sales of its hay fever range, GSK brought the Prinase hay fever Nasal Spray (formerly Flixonase Allergy Nasal Spray) under its umbrella Piri brand, in an attempt to capitalise on the equity of its Piriton brand range. The range was supported by a TV campaign and a new website.

PROSPECTS

  • The cough, cold and allergy remedies category is forecast to grow by a CAGR of 2% between 2011 and 2016. Adults experience between two and four colds every year, according to NHS data, and it is believed that there are over 200 cold viruses in circulation. The market is highly seasonal, being dependent on the severity of cold winters and pollen counts in the summer, influencing the number of cold/flu and hay fever sufferers.

CATEGORY DATA

  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 33 Sales of Decongestants by Category: Value 2006-2011
  • Table 34 Sales of Decongestants by Category: % Value Growth 2006-2011
  • Table 35 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 36 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2007-2011
  • Table 38 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2008-2011
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2011-2016
  • Table 40 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2011-2016

Digestive Remedies in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • The digestive remedies category in the UK achieved marginal 1% current value growth in 2011, to reach £292 million. Healthier lifestyles and a certain lack of public awareness of digestive remedy solutions has restrained growth in the category. The wider availability of private label and generic alternatives has also had the effect of depressing value growth.

SWITCHES

COMPETITIVE LANDSCAPE

  • Following its purchase of SSL International Plc, Reckitt Benckiser Plc cemented its lead in digestive remedies in 2011, with a 35% value share. Its Gaviscon and Senokot brands are market leaders in their respective antacid and laxative categories, while the SSL international purchase added strongly performing smaller brands, such as Remegel, Resolve and Diocalm, to its product stable. It invests in heavy marketing support for the Gaviscon brand (reportedly spending £11 million in 2011) and the “Gaviscon Fireman” is an iconic figure and provides both strong brand identity and, according to industry sources, helps drive sales in the wider digestive remedies category. Gastrocote was launched into the OTC market in 2011 by the generics manufacturer Actavis UK Ltd, and is expected to provide some competition to Gaviscon’s dominance in coming years.

PROSPECTS

  • Over the forecast period, the digestive remedies environment is expected to stagnate, experiencing only marginally positive constant value CAGR, to reach £295 million at constant 2011 prices in 2016. Digestive remedies is by and large a mature, saturated category, and in the UK digestive health problems tend to be prescribed for, which means scope for growth is highly restricted.

CATEGORY DATA

  • Table 41 Sales of Digestive Remedies by Category: Value 2006-2011
  • Table 42 Sales of Digestive Remedies by Category: % Value Growth 2006-2011
  • Table 43 Digestive Remedies Company Shares by Value 2007-2011
  • Table 44 Digestive Remedies Brand Shares by Value 2008-2011
  • Table 45 Forecast Sales of Digestive Remedies by Category: Value 2011-2016
  • Table 46 Forecast Sales of Digestive Remedies by Category: % Value Growth 2011-2016

Ear Care in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • The ear care category increased by 5% in 2011, to £11 million. Ear care is a concentrated category, with a few dominant companies. Firms are looking to differentiate themselves to gain market share from leader Dendron Ltd.

SWITCHES

COMPETITIVE LANDSCAPE

  • Dendron Ltd is the market leader in ear care, with sales of just over £3 million in 2011. The company’s Otex is the leading brand, with a 30% value share. Otex benefits from offering the dual action of both cleaning the ears and dispersing ear wax.

PROSPECTS

  • The category is forecast to grow marginally between 2006 and 2011, with a CAGR of 1% in constant value terms, to a total of £11 million at constant 2011 prices. The ear care category is very concentrated and new product developments will cause minimal growth.

CATEGORY DATA

  • Table 47 Sales of Ear Care: Value 2006-2011
  • Table 48 Sales of Ear Care: % Value Growth 2006-2011
  • Table 49 Ear Care Company Shares by Value 2007-2011
  • Table 50 Ear Care Brand Shares by Value 2008-2011
  • Table 51 Forecast Sales of Ear Care: Value 2011-2016
  • Table 52 Forecast Sales of Ear Care: % Value Growth 2011-2016

Emergency Contraception in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • In 2011, sales of emergency contraceptive increased by 10%, to reach £25 million. Bayer Plc’s dominance is being challenged (although not significantly) by Boots private label Emergency Contraceptive Pill, which was launched in October 2010

COMPETITIVE LANDSCAPE

  • Bayer Plc is the market leader, with a 93% value share in 2011. To date there are currently two forms of OTC emergency contraceptive: Bayer Plc’s Levonelle One Step and Boots’ Emergency Contraceptive Pill. There is scope for other manufacturers – both multinationals and private label – to gain market share by introducing there own versions of “the morning after pill”.

PROSPECTS

  • Sales of emergency contraceptive will continue to increase over the forecast period, with a CAGR of 3% in constant value terms.

CATEGORY DATA

  • Table 53 Sales of Emergency Contraception: Value 2006-2011
  • Table 54 Sales of Emergency Contraception: % Value Growth 2006-2011
  • Table 55 Emergency Contraception Company Shares by Value 2007-2011
  • Table 56 Emergency Contraception Brand Shares by Value 2008-2011
  • Table 57 Forecast Sales of Emergency Contraception: Value 2011-2016
  • Table 58 Forecast Sales of Emergency Contraception: % Value Growth 2011-2016

Eye Care in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • In 2011, eye care sales in the UK were worth £58 million, up 6% on 2010 market value. The market was driven by sales of standard eye care products which grew by 6% to reach sales of £48 million. Sales of allergy eye care products increased by 3% to almost reach £10 million, their sales partly affected by a low pollen season in 2011.

SWITCHES

COMPETITIVE LANDSCAPE

  • Reckitt Benckiser Plc is the market leader in the eye care market in 2011 with 45% value share. The company’s Optrex ActiMist spray has seen huge growth since its launch in 2009 and has become the UK’s top selling eye care treatment brand. Optrex ActiMist, used in the treatment of dry eye, was boosted by a £3 million TV and press advertising campaign.

PROSPECTS

  • Over 2011-2016 the eye care category is expected to see a 2% constant value CAGR. Standard eye care is expected to outperform allergy eye care over the forecast period, although it is anticipated that sales of allergy eye care will increase in line with a rise of allergies amongst the UK population.

CATEGORY DATA

  • Table 59 Sales of Eye Care by Category: Value 2006-2011
  • Table 60 Sales of Eye Care by Category: % Value Growth 2006-2011
  • Table 61 Standard Eye Care by Format: % Value Breakdown 2007-2011
  • Table 62 Standard Eye Care by Positioning: % Value Breakdown 2007-2011
  • Table 63 Eye Care Company Shares by Value 2007-2011
  • Table 64 Eye Care Brand Shares by Value 2008-2011
  • Table 65 Forecast Sales of Eye Care by Category: Value 2011-2016
  • Table 66 Forecast Sales of Eye Care by Category: % Value Growth 2011-2016

Herbal/Traditional Products in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • Herbal/traditional products grew by 4% in 2011, to reach sales of £469 million. Consumers are increasingly accepting herbal/traditional products as a means of treating their ailments, both as an alternative and complement to non-herbal remedies. Branded manufacturers are responding, with more herbal/traditional products appearing on the market.

COMPETITIVE LANDSCAPE

  • In 2011, Ernest Jackson Ltd led within herbal/traditional products, with 9% of sales value. The majority of its sales are achieved through its Halls brand of medicated confectionery. Halls Soothers and Mentho-Lyptus lead in medicated confectionery, and Halls occupied first places in herbal/traditional products in 2011, with a brand share of 8%. The company boosted sales of its Soothers range with a £1 million television advertising campaign in early 2011, the first time the brand had been the focus of a TV advertising campaign since 2005.

PROSPECTS

  • Herbal/traditional products are expected to see a CAGR of 1% in constant value terms over the forecast period. The trend towards consumers adopting herbal/traditional products to treat their ailments will continue.

CATEGORY DATA

  • Table 67 Sales of Herbal/Traditional Products: Value 2006-2011
  • Table 68 Sales of Herbal/Traditional Products: % Value Growth 2006-2011
  • Table 69 Herbal/Traditional Products Company Shares 2007-2011
  • Table 70 Herbal/Traditional Products Brand Shares 2008-2011
  • Table 71 Forecast Sales of Herbal/Traditional Products: Value 2011-2016
  • Table 72 Forecast Sales of Herbal/Traditional Products: % Value Growth 2011-2016

Medicated Skin Care in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • Sales of medicated skin care declined marginally in 2011, to £285 million. Paediatric medicated skin care and hair loss treatments were the fastest growing categories, as sales increased by 6% and 4%, respectively. Topical allergy remedies/antihistamines and antipruritics and antipruritics were the only other categories to see growth of over 2%.

SWITCHES

COMPETITIVE LANDSCAPE

  • Bayer Plc leads, with a 17% value share in 2011. The company dominates the vaginal antifungals category, with 74% of value, and has significant presence in haemorrhoids treatments, nappy (diaper) rash treatments, topical germicidals/antiseptics and antipruritics.

PROSPECTS

  • Sales of medicated skin care are expected to see an annual average decline in constant value terms over the forecast period. The economic climate shows no signs of improving, which is affecting consumer budgets and their spending habits. Certain categories, like paediatric products will, however, not be badly affected, as parents tend not to scrimp on products for their children. Paediatric medicated skin care is forecast to grow by a near 3% CAGR in constant value terms between 2011 and 2016.

CATEGORY DATA

  • Table 73 Sales of Medicated Skin Care by Category: Value 2006-2011
  • Table 74 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
  • Table 75 Medicated Skin Care Company Shares by Value 2007-2011
  • Table 76 Medicated Skin Care Brand Shares by Value 2008-2011
  • Table 77 Hair Loss Treatments Brand Shares by Value 2008-2011
  • Table 78 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
  • Table 79 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016

NRT Smoking Cessation Aids in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • Retail sales of NRT smoking cessation aids in the UK grew by 4% in current value terms in 2011, to reach £117 million. This was ahead of the CAGR of 3% over the review period, which can be attributed to new product development in a category which responds strongly to innovation.

SWITCHES

COMPETITIVE LANDSCAPE

  • McNeil Healthcare (UK) Ltd led the market in 2011, with a 37% total value share for its Nicorette brand. GlaxoSmithKline Plc’s Niquitin ranked second, with 30%, while Nicotinell from Novartis Consumer Health UK Ltd was third, with 20%. Nicorette was the leading brand throughout the review period; however, its value share decreased slightly from 38% in 2006 to 37% in 2011. This slight slippage can be attributed to new product development on the part of other players and the – albeit very gradual – increase in private label alternatives.

PROSPECTS

  • Over the forecast period, sales of NRT smoking cessation aids are expected to see a 2% CAGR in constant value terms. Sustained government policy initiatives encouraging quitting, alongside tobacco control legislation impeding the accessibility and visibility of tobacco products will continue to have a positive influence on the category. However, the expected rapid growth in the adjacent but separate arena of alternative nicotine delivery products is expected to curtail growth.

CATEGORY INDICATORS

  • Table 80 Number of Smokers by Gender 2006-2011

CATEGORY DATA

  • Table 81 Sales of NRT Smoking Cessation Aids by Category: Value 2006-2011
  • Table 82 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2006-2011
  • Table 83 NRT Gum Flavours: % Value Breakdown 2006-2011
  • Table 84 NRT Smoking Cessation Aids Company Shares by Value 2007-2011
  • Table 85 NRT Smoking Cessation Aids Brand Shares by Value 2008-2011
  • Table 86 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2011-2016
  • Table 87 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2011-2016

OTC Triptans in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • In 2011, sales of triptans were worth £6 million. Rising anxiety and stress levels caused by concerns over job and financial security are causing a rise in migraines and headaches in general. It is important for a pharmacist to distinguish between a headache and migraine, as common analgesics can be ineffective for migraines.

SWITCHES

COMPETITIVE LANDSCAPE

  • In 2011, Imigran Recovery was the only OTC treatment available for the treatment of migraines and therefore has a 100% value share, with sales of £6 million in 2011.

PROSPECTS

  • Over the 2011-2016 forecast period, OTC triptans is expected to see a CAGR of 8% in constant value terms. Negative forecasts regarding the future of the economy are causing changing lifestyle factors, rising unemployment levels, job insecurity and overall financial concerns. Rising stress and anxiety levels are causing migraines and increasing demand for triptans.

CATEGORY DATA

  • Table 88 Sales of OTC Triptans: Value 2006-2011
  • Table 89 Sales of OTC Triptans: % Value Growth 2006-2011
  • Table 90 OTC Triptans Company Shares by Value 2007-2011
  • Table 91 OTC Triptans Brand Shares by Value 2008-2011
  • Table 92 Forecast Sales of OTC Triptans: Value 2011-2016
  • Table 93 Forecast Sales of OTC Triptans: % Value Growth 2011-2016

Sports Nutrition in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • Retail value sales of sports nutrition products grew by 14% in 2011, to reach £230 million. A continued emphasis on fitness and sporting participation, and heavy marketing activity from the major brands has kept sales strong. The current value CAGR over 2006-2011 was 18%. Historically, the category experienced slightly stronger growth in retail value sales because of low penetration rates, and there remains very large capacity for growth. Expansion into wider distribution channels particularly in grocery and ever increasing public awareness and acceptance of sports nutrition products is driving growth.

COMPETITIVE LANDSCAPE

  • Maxinutrition Ltd remains the clear market leader within sports nutrition, with 35% of overall value sales and with primacy in all four of powder, bars, RTDs and non-protein (38%, 37%, 49% and 30% shares, respectively). It is followed by Holland & Barrett Retail Ltd with its own brand – Precision Engineered – on 14%. The third player in the market is Hut Group Ltd, with a 10% value share. A further 20% is dispersed between CNP Professional Ltd, USN UK Ltd, Reflex Nutrition Ltd, PhD Nutrition Ltd and Sci-Mx Nutrition LLP. Due to the sustained growth in the category, most players saw double-digit growth in value sales in 2011.

PROSPECTS

  • Over the forecast period, sports nutrition is expected to see a 12% constant value CAGR, to reach £414 million at constant 2011 prices by 2016. With the NHS Information Centre reporting in 2011 that almost a quarter of adults participate in sports on a regular basis, while according to industry sources less than 10% of them currently use sports nutrition products, there is clearly significant scope for strong growth. The wider distribution of sports nutrition products through supermarkets and – in the case of bars and RTDs – smaller grocers and vending machines, will help to demystify the category to the mainstream of physically active consumers and result in increased volume sales.

CATEGORY DATA

  • Table 94 Sales of Sports Nutrition: Value 2006-2011
  • Table 95 Sales of Sports Nutrition: % Value Growth 2006-2011
  • Table 96 Sports Nutrition Company Shares 2007-2011
  • Table 97 Sports Nutrition Brand Shares 2008-2011
  • Table 98 Forecast Sales of Sports Nutrition: Value 2011-2016
  • Table 99 Forecast Sales of Sports Nutrition: % Value Growth 2011-2016

Vitamins and Dietary Supplements in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • Consumer demand for vitamins and dietary supplements showed little sign of abating in 2011, despite difficult economic conditions. It is clear that there has been a shift away from some categories, particularly single vitamins or dietary supplements, with less certain health benefits, towards categories such as multivitamins which are perceived to provide value for money. Private label also continues to make inroads in a market which had previously been somewhat immune to its advantages. A changing distribution landscape is also beginning to impact, with more and more sales made on-line.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • In a fragmented marketplace, 2011 saw little real change in the shape of the competitive landscape. Holland & Barrett Retail Ltd ranked number one once more within the category, increasing its value share to 14%. Seven Seas Ltd and Vitabiotics Ltd also marginally increased their shares of vitamins and dietary supplements, and ranked second and third, respectively, with value shares of 10% and 9%.

PROSPECTS

  • Over the forecast period, the vitamins and dietary supplements environment is projected to see a constant value CAGR of 2%, to reach £846 million at constant 2011 prices in 2016. Increasingly health conscious consumers, an ageing UK population and product innovation will drive growth in the category over the forecast period.

CATEGORY DATA

  • Summary 29 Dietary Supplements: Brand Ranking by Positioning 2011
  • Table 100 Sales of Vitamins and Dietary Supplements by Category: Value 2006-2011
  • Table 101 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2006-2011
  • Table 102 Dietary Supplements by Positioning 2006-2011
  • Table 103 Vitamins and Dietary Supplements Company Shares by Value 2007-2011
  • Table 104 Vitamins and Dietary Supplements Brand Shares by Value 2008-2011
  • Table 105 Vitamins Brand Shares by Value 2008-2011
  • Table 106 Dietary Supplements Brand Shares by Value 2008-2011
  • Table 107 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2011-2016
  • Table 108 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2011-2016

Weight Management in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • Retail sales of weight management products in the UK declined by 2% in current value terms in 2011, to £126 million. The sharp slump of GlaxoSmithKline Plc’s OTC obesity pill Alli (value sales decline of 20%) had a major impact on the category. Excluding Alli’s OTC obesity, weight management enjoyed current value growth of 3% in 2011. This reflects a feeling expressed in trade interviews that notwithstanding its more recent loss of market credibility, the product has helped to attract new consumers to the category.

COMPETITIVE LANDSCAPE

  • Thanks to its Slimfast brand, Unilever Foods UK Ltd leads in weight management, with a 25% value share of retail sales, GlaxoSmithKline Plc ranks second, with a 16% value share of the category, and Herbalife follows with 11%.

PROSPECTS

  • Over the forecast period, the weight management category is expected to experience a marginal constant value CAGR, to reach £129 million at constant 2011 prices. Meal replacement slimming and weight loss supplements are each forecast to see constant value growth CAGRs of 2%; however, the category as a whole will be impacted by the projected continuing poor performance of Alli, with an annual average decline of 9% in constant value terms over the forecast period, to retail value sales of £12 million at constant 2011 prices, less than half of the revenue it generated in 2009.

CATEGORY DATA

  • Table 109 Sales of Weight Management: Value 2006-2011
  • Table 110 Sales of Weight Management: % Value Growth 2006-2011
  • Table 111 Weight Management Company Shares 2007-2011
  • Table 112 Weight Management Brand Shares 2008-2011
  • Table 113 Forecast Sales of Weight Management: Value 2011-2016
  • Table 114 Forecast Sales of Weight Management: % Value Growth 2011-2016

Wound Care in the United Kingdom - Category Analysis

HEADLINES

TRENDS

  • In 2011, the wound care category was worth £57 million, a decrease of 3% in current value terms from 2010. The category has been steadily declining since 2007. The growth in sales of supermarkets and other private label suppliers of plasters and bandages are driving down sales values and undercutting the more expensive branded manufacturers.

SWITCHES

COMPETITIVE LANDSCAPE

  • Beiersdorf UK Ltd was the category leader in 2011 with a 33% value share. The company has presence in all three categories: first aid kits, sticking plasters/adhesive bandages, and gauze, tape and other wound care, and is the leader in all three. However, the company faces stiff competition from private label.

PROSPECTS

  • Wound care sales are expected to decline by an annual average of 3% in constant value terms over the forecast period, to £50 million at constant 2011 prices.

CATEGORY DATA

  • Table 115 Sales of Wound Care by Category: Value 2006-2011
  • Table 116 Sales of Wound Care by Category: % Value Growth 2006-2011
  • Table 117 Wound Care Company Shares by Value 2007-2011
  • Table 118 Wound Care Brand Shares by Value 2008-2011
  • Table 119 Forecast Sales of Wound Care by Category: Value 2011-2016
  • Table 120 Forecast Sales of Wound Care by Category: % Value Growth 2011-2016

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Paediatric Analgesics
            • Paediatric Acetaminophen
            • Paediatric Aspirin
            • Paediatric Combination Products - Analgesics
            • Paediatric Diclofenac
            • Paediatric Dipyrone
            • Paediatric Ibuprofen
            • Paediatric Ketoprofen
            • Paediatric Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Paediatric Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
      • Protein Products
        • Bars
        • Powder
        • RTD
        • Other Protein
      • Non-Protein Products
    • Vitamins and Dietary Supplements
      • Paediatric Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Artichoke
            • Flaxseed/Linseed
            • Milk Thistle
            • Starflower Oil
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
        • Tonics and Bottled Nutritive Drinks
        • Vitamins
          • Multivitamins
          • Single Vitamins
            • Vitamin A
            • Vitamin B
            • Vitamin C
            • Vitamin D
            • Vitamin E
            • Other Single Vitamins
      • Weight Management
        • Meal Replacement Slimming
        • OTC Obesity
        • Slimming Teas
        • Weight Loss Supplements
        • Other Slimming Products
      • Herbal/Traditional Products
        • Herbal/Traditional Analgesics
        • Herbal/Traditional Calming and Sleeping Products
        • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
        • Herbal/Traditional Digestive Remedies
        • Herbal/Traditional Medicated Skin Care
        • Herbal/Traditional Medicinal Teas
        • Herbal/Traditional Smoking Cessation Aids
        • Herbal/Traditional Paediatric Dietary Supplements
        • Herbal/Traditional Dietary Supplements
        • Herbal/Traditional Tonics and Bottled Nutritive Drinks
      • Allergy Care
        • Allergy Eye Care
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Allergy Remedies
        • Topical Allergy Remedies/Antihistamines
      • Paediatric Consumer Health
        • Paediatric Analgesics
          • Paediatric Acetaminophen
          • Paediatric Aspirin
          • Paediatric Combination Products - Analgesics
          • Paediatric Diclofenac
          • Paediatric Dipyrone
          • Paediatric Ibuprofen
          • Paediatric Ketoprofen
          • Paediatric Naproxen
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Paediatric Medicated Skin Care
        • Nappy (Diaper) Rash Treatments
        • Paediatric Vitamins and Dietary Supplements

    Statistics Included

    Statistics Included

    For each category and subcategory you will receive the following data in Excel format:

    From Passport

    • Market sizes
    • Company shares
    • Brand shares
    • Distribution
    • Analysis by format
    • Analysis by positioning
    • Analysis by type
    • Herbal/traditional vs standard
    • Pricing
    • Smoking population - number of adult smokers
    • Smoking prevalence - % of adult population

    Market size details:

    • Retail volume
    • Retail volume % growth
    • Retail volume per capita
    • Retail value retail selling price % growth
    • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price % growth
    • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY

    Methodology

    Methodology

    Global insight and local knowledge

    With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

    This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

    Industry specialists

    Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

    Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

    The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

    Country and regional analysts

    Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

    In-country research network

    To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

    Research Methodology

    Our research methods

    Each Euromonitor International industry report is based on a core set of research techniques:

    Desk research

    With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

    • National statistics offices governmental and official sources
    • National and international trade press
    • National and international trade associations
    • Industry study groups and other semi-official sources
    • Company financials and annual reports
    • Broker reports
    • Online databases
    • The financial, business and mainstream press

    Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

    Store checks

    Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

    • Place: We track products in all relevant channels, selective and mass, store and non-store
    • Product: What are innovations in products, pack sizes and formats?
    • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
    • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

    Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

    Trade survey

    Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

    Trade surveys allow us to:

    • Fill gaps in available published data per company
    • Generate a consensus view of the size, structure and strategic direction of the category
    • Access year-in-progress data where published sources are out of date
    • Evaluate the experts’ views on current trends and market developments

    In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

    Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

    Company analysis

    At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

    At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

    Forecasts

    Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

    Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

    Data validation

    All data is subjected to an exhaustive review process, at country, regional and global levels.

    The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

    Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

    Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

    Market analysis

    Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

    Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

    my pages

    Want to find out more about this report?

    If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!